Ascletis Pharma-B (01672) has unveiled its financial results for the six months ended June 30, 2026. The company recorded total revenue of RMB 52.979 million, representing a year-on-year decrease of 48.9%. Research and development costs surged by 132.7% to RMB 342 million, while the loss attributable to equity shareholders widened by 263.5% to RMB 320 million. The basic loss per share stood at RMB 30.74 cents.

During the reporting period and up to the date of this announcement, the group has made significant strides in its immunology pipeline. ASC50, an oral small-molecule IL-17A inhibitor, has successfully completed a Phase I SAD study in healthy US subjects and a 28-day US Phase I proof-of-concept (POC) study (200 mg QD) in patients with mild-to-moderate plaque psoriasis. Human data suggests that ASC50 has the potential to be a first-in-class and best-in-class oral small-molecule IL-17A inhibitor. ASC51, a potent, selective, once-daily oral STAT6 degrader, is an IND-ready candidate for submission to the FDA, with all necessary preparatory studies for the FDA IND now complete. It is poised to become the second oral small-molecule STAT6 degrader of its kind, following KT-62. ASC52, which aims to be a best-in-class oral cyclic peptide antagonist targeting IL-17AA, AF, and FF, is expected to have its IND filed with the FDA in the fourth quarter of 2026. It is projected to be the second oral cyclic peptide antagonist of this class after PN-881. These achievements underline the group's robust research capabilities, outstanding execution, and long-term commitment to developing globally best-in-class or first-in-class pipeline drugs to address unmet clinical needs. The sharp increase in R&D expenditure is primarily driven by the group's strategic commitment to advancing its comprehensive metabolic disease pipeline, encompassing both small molecules and peptides.